EcoDrugPlus

P21 Protein (Cdc42/rac)-Activated Kinase 4

Ensembl ID : ENSOMYG00000040226
Gene Symbol: PAK4
1 Cross references
166 Possible Orthologues:

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSOMYG00000040693
Gene Symbol: PTH1R
2 Cross references
190 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Gamma

Ensembl ID : ENSOMYG00000006827
Gene Symbol: PPARG
2 Cross references
389 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Alpha B

Ensembl ID : ENSOMYG00000012946
Gene Symbol: PPARAB
1 Cross references
390 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Alpha B

Ensembl ID : ENSOMYG00000022080
Gene Symbol: PPARAB
1 Cross references
390 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Delta B

Ensembl ID : ENSOMYG00000025767
Gene Symbol: PPARDB
1 Cross references
389 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSOMYG00000001449
Gene Symbol: PIK3CA
1 Cross references
191 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSOMYG00000024649
Gene Symbol: PIK3CA
1 Cross references
150 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta

Ensembl ID : ENSOMYG00000043608
Gene Symbol: PIK3CB
1 Cross references
209 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase, Catalytic Subunit Delta

Ensembl ID : ENSOMYG00000027661
Gene Symbol: PIK3CD
1 Cross references
213 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase, Catalytic Subunit Gamma

Ensembl ID : ENSOMYG00000045201
Gene Symbol: PIK3CG
1 Cross references
207 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase, Catalytic Subunit Gamma

Ensembl ID : ENSOMYG00000042114
Gene Symbol: PIK3CG
1 Cross references
207 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).